ABCB1 and breast carcinoma: Treatment of breast cancer cells with an EGFR/HER2 inhibitor lapatinib, resulted in a decrease in ABCB1 and ABCG2 expression, thereby sensitizing breast cancer cells to a chemotherapeutic agent doxorubicin 302.